The Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab in Patients With Locally Recurrent or Metastatic Triple-Negative Breast Cancer

As antiangiogenic agents could enhance the response to immune checkpoint inhibitors, investigators conducted this phase 2 study to assess the efficacy and safety of the novel chemotherapy-free regimen of sitravatinib (targets receptor TKI against TYRO3, AXL, MERTK and VEGF family of receptors) in combination with tislelizumab (anti-PD-1 antibody) in patients with locally recurrent or metastatic TNBC regardless of PD-L1 status. Sitravatinib combined with tislelizumab demonstrated clinically meaningful anti-tumor activity and had a manageable safety profile.